Phase IV, multicenter, randomized, single-blind, study to evaluate the immunogenicity, reactogenicity amp; safety of the live attenuated rotavirus vaccine ROTAVAC as a 3 dose series when administered simultaneously with or without the buffering agent following in healthy infants - ROTAVAC

Next Previous
Trial Profile

Phase IV, multicenter, randomized, single-blind, study to evaluate the immunogenicity, reactogenicity amp; safety of the live attenuated rotavirus vaccine ROTAVAC as a 3 dose series when administered simultaneously with or without the buffering agent following in healthy infants - ROTAVAC

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Mar 2018

At a glance

  • Drugs ORV 116E (Primary)
  • Indications Rotavirus infections
  • Focus Pharmacodynamics
  • Sponsors Bharat Biotech

    • Most Recent Events

    • 06 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top